Actively Recruiting
Longitudinal Data Registry of Plasma Cell Dyscrasia
Led by Shanghai Zhongshan Hospital · Updated on 2025-01-06
2000
Participants Needed
1
Research Sites
304 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to identify clinical characteristics, response and clinical outcome of plasma cell dyscrasia (PCD) diagnosed in Zhongshan Hospital, Fudan University from May 2023. In its current version, the registry incorporates historical data (collected from 2007) and is prospectively collecting follow-up data and recording patient outcomes.
CONDITIONS
Official Title
Longitudinal Data Registry of Plasma Cell Dyscrasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with plasma cell dyscrasia (e.g., symptomatic/asymptomatic multiple myeloma, MGUS, POEMS syndrome, AL amyloidosis) from 2007 to 2027 at Zhongshan Hospital
- Patients with complete diagnostic, treatment, and follow-up records
- Patients who fully understand and sign the informed consent form for participation
You will not qualify if you...
- Patients who refuse to use reliable contraception during pregnancy, lactation, or appropriate reproductive periods
- Patients with severe mental illness
- Patients deemed unsuitable for inclusion by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
P
Peng Liu, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here